EIKO Lifesciences Limited announced its unaudited financial results for the first quarter, along with several key corporate updates, in a board meeting held on July 29, 2025.

Financial Highlights

For Q1 (April-June 2025), Eiko LifeSciences reported:

• Consolidated revenue from operations of ₹1,071.15 lakhs, compared to ₹1,075.04 lakhs in Q1 of the previous year
• Consolidated profit after tax of ₹111.74 lakhs, a significant increase from ₹37.13 lakhs in the same quarter last year
• Earnings per share (EPS) of ₹0.66, up from ₹0.29 in Q1 of the previous year

The company's specialty and fine chemicals segment generated revenue of ₹840.22 lakhs, while the logistics business contributed ₹230.93 lakhs.

Board Changes and Appointments

The board announced several changes to its composition:

• Mr. Umesh More resigned as Whole Time Director, effective July 29, 2025
• Mr. Sumukh Prabhakar Vartak was appointed as additional Whole Time Director for a term of 5 years, subject to shareholder approval
• Ms. Kajal Kothari and Mr. Rajkumar Baheti were re-appointed as Independent Directors for second terms of 5 years each, pending shareholder approval

Increase in Authorized Share Capital

The board approved an increase in the company's authorized share capital from ₹14 crore to ₹20 crore. The proposed change will amend the Memorandum of Association, increasing the number of equity shares from 1.4 crore to 2 crore, each with a face value of ₹10. This decision is subject to shareholder approval.

Segment Performance

The company operates in two main segments:

Outlook

Laxmikant Kabra, Chairman of Eiko LifeSciences, commented on the results: "Our strong performance in Q1 demonstrates the resilience of our core specialty chemicals business and the growing contribution from our logistics segment. The board changes and proposed capital increase position us well for future growth opportunities."

The company will seek shareholder approval for the board appointments and capital increase at its upcoming 48th Annual General Meeting, scheduled for September 5, 2025.

Eiko LifeSciences continues to focus on its twin pillars of specialty chemicals and logistics services, with an eye on expanding its market presence and operational capabilities in both sectors.

Share Transfer and KYC Update

In line with SEBI directives, Eiko LifeSciences has opened a special window for re-lodgement of physical share transfer requests from July 7, 2025, to January 6, 2026. This applies to transfer deeds lodged before April 1, 2019, that were rejected or returned due to deficiencies. The company also reminded physical shareholders to update their PAN, KYC, and nomination details as mandated by SEBI.

EIKO Lifesciences Limited, a specialty chemicals manufacturer, has announced significant board changes and expansion plans at its upcoming 48th Annual General Meeting (AGM) scheduled for September 5, 2025. The company also reported strong financial performance for the first quarter of FY 2025-26.

Board Changes and Appointments

The company's board has undergone several changes:

• Mr. Umesh More has resigned as Whole Time Director, effective July 29, 2025, citing commitments to other business endeavors.
• Mr. Sumukh Prabhakar Vartak has been appointed as an additional Whole Time Director for a term of 5 years, subject to shareholder approval. Mr. Vartak brings over 21 years of experience in Active Pharmaceutical Ingredients (APIs).
• Ms. Kajal Kothari and Mr. Rajkumar Baheti have been proposed for re-appointment as Independent Directors for second terms of 5 years each.

Expansion Plans and Capital Increase

Eiko LifeSciences has announced plans to increase its Authorized Share Capital from Rs. 14 crore to Rs. 20 crore, divided into 2 crore equity shares of Rs. 10 each. This move is aimed at supporting the company's growth and future capital requirements.

Q1 FY 2025-26 Financial Highlights

For the quarter ended June 30, 2025, Eiko LifeSciences reported:

The company's performance was driven by strong results in both its Specialty & Fine Chemicals and Logistics Business segments.

Other AGM Matters

The 48th AGM will also address routine matters such as the adoption of financial statements and the re-appointment of Mr. Laxmikant Kabra as a director liable to retire by rotation.

Eiko LifeSciences has also announced a special window for re-lodgement of transfer requests for physical shares, in line with recent SEBI circulars. This window will be open from July 7, 2025, to January 6, 2026, allowing shareholders to complete pending transfer requests.

The company continues to focus on its core specialty chemicals business while expanding into logistics through its subsidiary, reflecting its strategy for diversified growth.